Watch for updates on Phase I safety/efficacy data readouts and the completion of antitrust reviews for the GSK license agreement. The GSK partnership provides a strong validation of the ATTC platform and de-risks ex-China development costs.
Price Chart
Executive Summary
HUTCHMED announced the initiation of a global Phase Ia clinical trial for HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate (ATTC), in patients with advanced solid tumors. The first patient was dosed in China on September 24, 2026. This trial follows a September 3, 2026 licensing agreement with a GSK subsidiary, which granted GSK worldwide rights (ex-China) to develop and commercialize HMPL-A830, with HUTCHMED responsible for the global Phase I program.
Key Facts
- Phase Ia global trial of HMPL-A830 initiated; first patient dosed in China on September 24, 2026.
- HMPL-A830 is a first-in-class ATTC combining a KRAS small molecule inhibitor payload with an anti-EGFR antibody.
- On September 3, 2026, HUTCHMED entered an exclusive license agreement with a GSK subsidiary for worldwide rights (ex-China) to develop and commercialize HMPL-A830.
- HUTCHMED retains responsibility for the global Phase I development; GSK will handle all subsequent development and commercialization outside China, Hong Kong, Macau, and Taiwan.
- The agreement is subject to customary closing conditions, including antitrust regulatory reviews.
- Target indications include KRAS-altered colorectal, pancreatic, and lung cancers.
Financial Impact
No financial terms of the GSK license agreement were disclosed. The trial initiation itself has no direct near-term revenue impact but validates the ATTC platform and partnership with GSK.
Risk Factors
- Phase I clinical trials have a high failure rate; early safety or efficacy issues could halt development.
- The GSK license agreement is subject to antitrust regulatory approvals, which could be delayed or denied.
- HMPL-A830 is a first-in-class molecule with no prior clinical data; preclinical results may not translate to humans.
- KRAS-targeted therapies face competition from approved drugs (e.g., sotorasib, adagrasib) and other novel approaches.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000061 |
| Document: hcm-20260928x6k.htm | 0001648257-26-000061 |
| Document: 0001648257-26-000061-index-headers.html | 0001648257-26-000061 |
| Document: 0001648257-26-000061-index.html | 0001648257-26-000061 |
| Document: 0001648257-26-000061.txt | 0001648257-26-000061 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+20 | — | — |
Oct 26, 2026 today | Press Release | — | awaiting T+20 | — | — |
Oct 26, 2026 today | Press Release | — | awaiting T+20 | — | — |
Oct 21, 2026 5d ago | 6-K | $14.37 | awaiting T+20 | — | $14.30 (−0.49%) |
Sep 29, 2026 27d ago | 6-K | $14.15 | awaiting T+20 | — | $14.30 (+1.06%) |
Sep 28, 2026 27d ago | 6-K | $14.15 | awaiting T+20 | — | $14.30 (+1.06%) |
Sep 29, 2026 27d ago | Press Release | $14.63 | awaiting T+20 | — | $14.30 (−2.26%) |
Sep 24, 2026 4w ago | 6-K | $13.90 $14.28 | ▲ +2.73% | ▲ +3.15% | $14.30 (+2.88%) |
Sep 24, 2026 4w ago | Press Release | $13.94 $14.36 | ▲ +3.01% | ▲ +4.49% | $14.30 (+2.58%) |
Sep 3, 2026 7w ago | 6-K | $14.11 $14.20 | ▲ +0.64% | ▲ +1.83% | $14.30 (+1.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers